


GC Biopharma receives marketing authorisation for varicella vaccine BARYCELA in Vietnam

17 July 2025 | News

GC Biopharma plans to establish stable annual revenue in Vietnam



GC Biopharma, a South Korean pharmaceutical company, has announced that its varicella vaccine BARYCELA has received marketing authorisation from the Drug Administration of Vietnam (DAV).

Following domestic approval in 2020 and WHO Pre-Qualification (PQ) in 2023, GC Biopharma has been accelerating individual country registrations as part of its dual-track strategy, pursuing both global procurement channels and direct market entry initiatives.

To obtain approval in Vietnam, GC Biopharma conducted local clinical trials to establish the product's safety and immunogenicity. This achievement highlights the company's ability to meet the increasingly stringent regulatory standards set by DAV. As a vaccine administered primarily to children, quality certification holds particular importance in the varicella segment.

GC Biopharma plans to establish stable annual revenue in Vietnam by leveraging its local affiliate to engage directly in sales activities, in consideration of the country's private market-oriented vaccine distribution system.

From 2018 to 2021, Vietnam's private vaccine market recorded a compound annual growth rate (CAGR) of 32%, reaching

approximately \$300 million in 2021. Varicella vaccines accounted for nearly 10% of the private market, with demand for private vaccinations continuing to grow steadily.

BARYCELA is a live attenuated varicella vaccine developed by GC Biopharma using its proprietary MAV/06 virus strain. The vaccine is characterised by high viral titer and manufacturing yield. Notably, BARYCELA is the world's first varicella vaccine produced without antibiotics, utilising a fully aseptic manufacturing process.